Guidelines for the budget impact analysis of health technologies in Ireland

Health Information and Quality Authority
Record ID 32018002766
English
Authors' objectives: HTA guideline documents provide an overview of the principles and methods used in assessing health technologies. These are intended as a guide for everyone who is involved in the conduct or use of HTA in Ireland, promoting the production of assessments that are timely, reliable, consistent and relevant to the needs of decision-makers and key stakeholders in Ireland. These guidelines are intended to inform economic evaluations conducted by, or on behalf of the Health Information and Quality Authority (HIQA), the National Centre for Pharmacoeconomics, the Department of Health and the Health Service Executive (HSE), to include health technology suppliers preparing applications for reimbursement. The guidelines are intended to be applicable to all healthcare technologies, including pharmaceuticals, procedures, medical devices, broader public health interventions and service delivery models. This document, Guidelines for the Budget Impact Analysis of Health Technologies in Ireland, is part of the series of guidelines and is limited to methodological guidance on the conduct of economic assessments. The guidelines will be reviewed and revised as necessary.
Details
Project Status: Completed
Year Published: 2018
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Ireland
MeSH Terms
  • Budgets
  • Cost-Benefit Analysis
  • Costs and Cost Analysis
  • Technology Assessment, Biomedical
  • Guidelines as Topic
Keywords
  • Guidelines
  • Budget Impact Analysis
Contact
Organisation Name: Health Information and Quality Authority (HIQA)
Contact Address: Health Information and Quality Authority, George's Court, George's Lane,Smithfield, Dublin 7. PH : + 353 (01) 814 7464
Contact Name: info@hiqa.ie
Contact Email: info@hiqa.ie
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.